A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Chronic Idiopathic Constipation (CIC) in Adults
Ardelyx
692 participants
Jan 13, 2026
INTERVENTIONAL
Conditions
Summary
This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess the safety and efficacy of tenapanor (5 mg, 25mg, and 50 mg) in adult patients with Chronic Idiopathic Constipation (CIC) when administered twice daily for 26 consecutive weeks.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will receive tenapanor 5 mg BID (total of 10 mg daily)
Patients will receive tenapanor 25 mg BID (total of 50 mg daily)
Patients will receive tenapanor 50 mg BID (total of 100 mg daily)
Patients will receive matching placebo BID
Locations(109)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07382167